PGNY Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

31.360

Open

30.990

VWAP

30.77

Vol

1.13M

Mkt Cap

2.41B

Low

30.170

Amount

34.87M

EV/EBITDA(TTM)

20.44

Total Shares

78.33M

2.20B

EV/OCF(TTM)

10.65

P/S(TTM)

2.12

Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.

Events Timeline

(ET)

2026-05-26

08:30:00

Progyny Approves $200 Million Share Repurchase Program

2026-05-12 (ET)

2026-05-12

10:50:00

Trump Plans to Reduce Beef Import Tariffs

2026-05-12

10:00:00

KeyBanc Notes DOL Proposes New Rule for Fertility Treatments

2026-05-12

09:50:00

U.S. Departments Propose Expansion of Fertility Benefits

News

5.0

06-25Fool

Progyny CFO Mark Livingston's Stock Sale Analysis

5.0

06-25NASDAQ.COM

Progyny CFO Mark Livingston Sells Shares, Reduces Holdings

5.0

05-31NASDAQ.COM

Progyny Director Kevin Gordon Sells Shares

5.0

05-31Fool

Progyny Insider Sells Shares Amid Positive Market Outlook

6.5

05-28Newsfilter

Progyny Survey Reveals Importance of Human-Centric Healthcare

8.0

05-26seekingalpha

Progyny Approves $200M Share Repurchase Program

8 Analyst Rating

Wall Street analysts forecast PGNY stock price to rise

6 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

26.00

Averages

29.75

High

34.00

Current: 0.000

Low

26.00

Averages

29.75

High

34.00

Truist

Buy

maintain

$30 -> $33

AI Analysis

2026-06-22

Reason

Truist

Price Target

$30 -> $33

AI Analysis

2026-06-22

maintain

Buy

Reason

Truist raised the firm's price target on Progyny to $33 from $30 and keeps a Buy rating on the shares after hosting meetings with its management team. The key message from these meetings was that the company remains a highly differentiated fertility benefits platform, built around superior clinical outcomes, comprehensive member support, and deep provider network management, the analyst tells investors in a research note.

BofA

Buy

maintain

$29 -> $31

2026-06-02

Reason

BofA

Price Target

$29 -> $31

2026-06-02

maintain

Buy

Reason

BofA raised the firm's price target on Progyny to $31 from $29 and keeps a Buy rating on the shares. Fertility prescription trends and Google search trends suggest Q2 utilization and assisted reproductive technology cycle growth is trending favorably and signal potential upside to Street expectations in Q2, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PGNY

Unlock Now

Valuation Metrics

The current forward P/E ratio for Progyny Inc (PGNY.O) is 14.97, compared to its 5-year average forward P/E of 107.46. For a more detailed relative valuation and DCF analysis to assess Progyny Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

107.46

Current PE

14.97

Overvalued PE

296.94

Undervalued PE

-82.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

18.36

Current EV/EBITDA

13.51

Overvalued EV/EBITDA

31.59

Undervalued EV/EBITDA

5.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.97

Current PS

1.57

Overvalued PS

4.84

Undervalued PS

1.11

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

What US stocks have an RSI less the <20

Intellectia · 241 candidates

Rsi Category: oversoldList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

LBGJ

Li Bang International Corporation Inc

22.89M

RNA

Avidity Biosciences Inc

228.85M

XPOF

Xponential Fitness Inc

208.39M

MODD

Modular Medical Inc

19.20M

FLGT

Fulgent Genetics Inc

478.77M

Quhuo Ltd

3.33M

Whales Holding PGNY

Disciplined Growth Investors, Inc.

ArrowMark Colorado Holdings, LLC

Duquesne Family Office LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Progyny Inc (PGNY) stock price today?

The current price of PGNY is 30.78 USD — it has decreased -0.48

What is Progyny Inc (PGNY)'s business?

What is the price predicton of PGNY Stock?

Wall Street analysts forecast PGNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PGNY is29.75 USD with a low forecast of 26.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.